The efficacy, safety, and tolerability of levofloxacin quadruple therapy for helicobacter p lori eradication: a randomized, double-blind clinical trial

HIGHLIGHTS

  • who: Fariborz Mansour-Ghanaei and collaborators from the Caspian Digestive Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran have published the research work: The Efficacy, Safety, and Tolerability of Levofloxacin Quadruple Therapy for Helicobacter p lori Eradication: A Randomized, Double-Blind Clinical Trial, in the Journal: Evidence-Based Complementary and Alternative Medicine of 28/Nov/2021
  • what: Te BPAL-7 and BPAL-10 regimens were patientcompatible and well-tolerated.

SUMMARY

    Helicobacter pylori (H. pylori) afects about 80% of the total population in developing countries and 20-50% in developed . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?